Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.

Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Recent News

Viracta Announces the Appointment of Mark A. McCamish, MD, PhD as Strategic Advisor

Viracta Therapeutics, Inc., today announced that Mark A. McCamish, MD, PhD, has joined Viracta as a Strategic Advisor to the Company. Read More

Viracta Therapeutics Announces Appointment of Roger J. Pomerantz, MD to its Board of Directors

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Roger J. Pomerantz, MD, FACP, has been appointed to its Board of Directors. Read More

Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering its Combination Product Candidate for the Treatment of Viral or Virally-Induced Conditions

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 15/959,482. Read More

Viracta Therapeutics Announces Orphan Drug Designation Granted for the Treatment of T-cell Lymphoma

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that its Phase 2 all-oral combination product of nanatinostat and valganciclovir has been granted orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma. Read More

Events

June 5, 2020

Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma Read More | Watch Replay

February 25-27, 2020

Biocom's 10th Annual Global Life Science Partnering Conference, in La Jolla, CA Read More

February 20, 2020

16th Annual UCSD Moores Cancer Center Symposium, in San Diego, CA Read More

Recent News

Viracta Announces the Appointment of Mark A. McCamish, MD, PhD as Strategic Advisor

Viracta Therapeutics, Inc., today announced that Mark A. McCamish, MD, PhD, has joined Viracta as a Strategic Advisor to the Company. Read More

Viracta Therapeutics Announces Appointment of Roger J. Pomerantz, MD to its Board of Directors

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Roger J. Pomerantz, MD, FACP, has been appointed to its Board of Directors. Read More

Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering its Combination Product Candidate for the Treatment of Viral or Virally-Induced Conditions

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 15/959,482. Read More

Viracta Therapeutics Announces Orphan Drug Designation Granted for the Treatment of T-cell Lymphoma

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that its Phase 2 all-oral combination product of nanatinostat and valganciclovir has been granted orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma. Read More

Events

June 5, 2020

Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma Read More | Watch Replay

February 20, 2020

16th Annual UCSD Moores Cancer Center Symposium, in San Diego, CA Read More

February 25-27, 2020

Biocom's 10th Annual Global Life Science Partnering Conference, in La Jolla, CA Read More